Acusphere Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for approval to market its lead product candidate, Imagify™ (Perflubutane Polymer ...
SAN FRANCISCO (MarketWatch) -- Acusphere Inc. ACUS, shares tumbled 27% to $3.02 in Tuesday morning trade. The Watertown, Mass.-based pharmaceutical company said Imagify met the primary endpoints for ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, today announced that it had reached an agreement with the U.S. Food & Drug Administration (FDA) ...
TEWKSBURY, Mass., Dec 15, 2009 (BUSINESS WIRE) -- Acusphere, Inc. (ACUS.PK) today announced that co-founder and CEO, Sherri C. Oberg, will assume a new role as Executive Chair, working 20% of her time ...
WATERTOWN, Mass., Dec 10, 2008 (BUSINESS WIRE) -- Acusphere, Inc. today announced that NASDAQ has halted trading in the Company's common stock today. The Cardio Renal Advisory Committee to the U.S.
Cephalon is paying $20 million in up-front financing to Acusphere for an exclusive worldwide license to AI-525, a preclinical-stage injectable form of the anti-inflammatory drug celecoxib, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results